Skip to main content

Magenta Therapeutics, Inc. (MGTA)

NASDAQ: MGTA · IEX Real-Time Price · USD
6.06 -0.51 (-7.76%)
Nov 26, 2021 1:00 PM EST - Market closed
Market Cap361.87M
Revenue (ttm)n/a
Net Income (ttm)-70.01M
Shares Out59.71M
EPS (ttm)-1.34
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume188,815
Open7.08
Previous Close6.57
Day's Range5.95 - 6.50
52-Week Range5.89 - 14.20
Beta2.02
AnalystsStrong Buy
Price Target13.17 (+117.3%)
Earnings DateNov 4, 2021

About MGTA

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to bring the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. The company is developing C100 and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of g...

IndustryBiotechnology
Founded2015
CEOJason Gardner
Employees73
Stock ExchangeNASDAQ
Ticker SymbolMGTA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for MGTA stock is "Strong Buy." The 12-month stock price forecast is 13.17, which is an increase of 117.33% from the latest price.

Price Target
$13.17
(117.33% upside)
Analyst Consensus: Strong Buy

News

Big Pharma Is Going Holiday Shopping. Who's Next?

After an infusion of cash from COVID-19 treatments, many companies are on the lookout for acquisitions.

Other symbols:CCXIEPZMHCM
2 weeks ago - The Motley Fool

Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transpla...

3 weeks ago - Business Wire

Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 A...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to...

3 weeks ago - Business Wire

Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transpla...

1 month ago - Business Wire

Magenta Therapeutics to Participate in 2021 Cantor Virtual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplan...

2 months ago - Business Wire

Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to mor...

2 months ago - Business Wire

Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to mo...

3 months ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA).  Such investors are advised...

3 months ago - PRNewsWire

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to mo...

3 months ago - Business Wire

Magenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA) today announced that it has received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its I...

4 months ago - Business Wire

After Plunging 21% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA)

Magenta Therapeutics, Inc. (MGTA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ear...

4 months ago - Zacks Investment Research

Magenta Therapeutics Appoints Caren Deardorf as Chief Commercial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to mo...

4 months ago - Business Wire

Magenta Therapeutics Appoints Thomas Beetham as Chief Legal Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more pat...

5 months ago - Business Wire

Magenta Therapeutics Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-14...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more pat...

5 months ago - Business Wire

Magenta Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more pat...

5 months ago - Business Wire

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more pat...

6 months ago - Business Wire

Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myelo...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more pat...

6 months ago - Business Wire

Magenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple Investors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to mor...

6 months ago - Business Wire

Magenta Therapeutics Reports First Quarter Financial Results and Recent Program Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more pat...

6 months ago - Business Wire

Magenta Therapeutics Appoints David Nichols as Chief Technical Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more pat...

7 months ago - Business Wire

Magenta Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more pat...

8 months ago - Business Wire

Magenta Therapeutics Presents Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more pat...

8 months ago - Business Wire

Magenta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more pat...

8 months ago - Business Wire

Magenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more pat...

8 months ago - Business Wire

Magenta Is Ready to Paint Your Portfolio Green

This clinical-stage biotech is looking to make stem cell transplantation faster, easier, and safer for both donors and patients.

8 months ago - The Motley Fool